Shikonin prolongs allograft survival via induction of CD4+Foxp3+ regulatory T cells

14Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

A transplanted organ is usually rejected without any major immunosuppressive treatment because of vigorous alloimmune responsiveness. However, continuous global immunosuppression may cause severe side effects, including nephrotoxicity, tumors, and infections. Therefore, it is necessary to seek novel immunosuppressive agents, especially natural ingredients that may provide sufficient efficacy in immunosuppression with minimal side effects. Shikonin is a bioactive naphthoquinone pigment, an ingredient originally extracted from the root of Lithospermum erythrorhizon. Previous studies have shown that shikonin regulates immunity and exerts anti-inflammatory effects. In particular, it can ameliorate arthritis in animal models. However, it is unclear whether shikonin inhibits alloimmunity or allograft rejection. In this study and for the first time, we demonstrated that shikonin significantly prolonged the survival of skin allografts in wild-type mice. Shikonin increased the frequencies of CD4+Foxp3+ regulatory T cells (Tregs) post-transplantation and induced CD4+Foxp3+ Tregs in vitro as well. Importantly, depleting the Tregs abrogated the extension of skin allograft survival induced by shikonin. It also decreased the frequencies of CD8+CD44highCD62Llow effector T cells and CD11c+CD80+/CD11c+CD86+ mature DCs after transplantation. Moreover, we found that shikonin inhibited the proliferation of T cells in vitro and suppressed their mTOR signaling. It also reduced the gene expression of pro-inflammatory cytokines, including IFNγ, IL-6, TNFα, and IL-17A, while increasing the gene expression of anti-inflammatory mediators IL-10, TGF-β1, and indoleamine-2, 3-dioxygenase (IDO) in skin allografts. Further, shikonin downregulated IDO protein expression in skin allografts and DCs in vitro. Taken together, shikonin inhibits allograft rejection via upregulating CD4+Foxp3+ Tregs. Thus, shikonin is a novel immunosuppressant that could be potentially used in clinical transplantation.

References Powered by Scopus

Control of regulatory T cell development by the transcription factor Foxp3

7197Citations
N/AReaders
Get full text

Foxp3 programs the development and function of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells

6531Citations
N/AReaders
Get full text

Conversion of Peripheral CD4<sup>+</sup>CD25<sup>-</sup> Naive T Cells to CD4<sup>+</sup>CD25<sup>+</sup> Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3

4042Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Shikonin, a naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches

95Citations
N/AReaders
Get full text

Anti-angiogenic effect of Shikonin in rheumatoid arthritis by downregulating PI3K/AKT and MAPKs signaling pathways

95Citations
N/AReaders
Get full text

Recent advances in shikonin for the treatment of immune-related diseases: Anti-inflammatory and immunomodulatory mechanisms

22Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zeng, Q., Qiu, F., Chen, Y., Liu, C., Liu, H., Liang, C. L., … Dai, Z. (2019). Shikonin prolongs allograft survival via induction of CD4+Foxp3+ regulatory T cells. Frontiers in Immunology, 10(APR). https://doi.org/10.3389/fimmu.2019.00652

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Professor / Associate Prof. 1

17%

Researcher 1

17%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 2

40%

Chemical Engineering 1

20%

Pharmacology, Toxicology and Pharmaceut... 1

20%

Nursing and Health Professions 1

20%

Save time finding and organizing research with Mendeley

Sign up for free